Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

6 of 3 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 1
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 1(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01133756Phase 1Terminated

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Role: collaborator

NCT01347645Phase 1Terminated

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Role: collaborator

NCT01127451Phase 2Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Role: collaborator

NCT01126749Phase 1Terminated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Role: collaborator

NCT01332266Phase 1Completed

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Role: collaborator

NCT01271504Phase 1Completed

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Role: collaborator

All 6 trials loaded